Articles

P.03 THE TRITON CLINICAL TRIAL PROGRAMME: EVALUATION OF THE POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY

BJMO - volume 12, issue 3, february 2018

B. Sautois MD, PhD, J.C. Goeminne MD, S. Rottey MD, PhD, D. Schrijvers MD, PhD, F. Van Aelst MD, S. Van Bruwaene MD, PhD, S. Watkins , A. Simmons , Jowell Go , Melanie Collins , T. Golsorkhi , W. Abida MD, PhD, C. Ryan , Howard Scher , S. Chowdhury

Read more